deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-26% certainty unassessablestatistically conclusive-22%-